Latest Ratios: P/E Ratio 14.0x · EV/EBITDA 12.1x · ROE 7.3%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $1.8B | $2.3B | $1.6B | $1.7B | $2.1B | $1.9B | $1.6B | $1.1B | $1.2B | $914M |
| Enterprise Value | $5.7B | $5.5B | $5.0B | $6.0B | $6.7B | $6.7B | $5.9B | $5.8B | $4.2B | $3.8B | $3.6B |
| P/E Ratio → | 13.99 | 12.58 | 11.36 | 6.63 | 10.87 | 5.29 | 7.72 | 8.16 | 7.80 | 10.93 | 8.21 |
| P/S Ratio | 0.38 | 0.34 | 0.45 | 0.23 | 0.26 | 0.33 | 0.35 | 0.30 | 0.21 | 0.28 | 0.21 |
| P/B Ratio | 1.00 | 0.90 | 1.18 | 0.99 | 1.20 | 1.51 | 1.17 | 0.86 | 1.05 | 1.18 | 0.92 |
| P/FCF | 5.35 | 4.79 | 4.35 | 4.42 | 17.64 | 9.34 | 2.19 | 5.68 | 3.30 | 251.23 | 4.94 |
| P/OCF | 5.91 | 5.29 | 4.54 | 2.68 | 5.85 | 5.14 | 1.88 | 3.68 | 2.18 | 5.16 | 2.64 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.01 | 0.96 | 0.90 | 1.06 | 1.09 | 1.06 | 1.06 | 0.83 | 0.86 | 0.83 |
| EV / EBITDA | 12.06 | 11.61 | 10.58 | 7.90 | 11.04 | 7.37 | 7.57 | 8.49 | 6.78 | 7.38 | 7.98 |
| EV / EBIT | 17.11 | 14.12 | 16.46 | 10.38 | 15.65 | 8.82 | 12.26 | 12.48 | 9.98 | 10.65 | 11.72 |
| EV / FCF | — | 14.40 | 9.25 | 17.09 | 71.20 | 30.58 | 6.64 | 20.16 | 12.83 | 778.51 | 19.21 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 11.5% | 11.5% | 12.2% | 14.0% | 11.6% | 14.8% | 14.8% | 14.9% | 14.6% | 16.0% | 14.5% |
| Operating Margin | 6.1% | 6.1% | 5.2% | 8.3% | 6.4% | 11.5% | 10.3% | 8.7% | 8.2% | 8.0% | 7.0% |
| Net Profit Margin | 2.7% | 2.7% | 4.1% | 3.7% | 2.5% | 6.5% | 4.7% | 2.7% | 2.7% | 4.0% | 2.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.3% | 7.3% | 12.0% | 16.4% | 11.5% | 26.7% | 14.6% | 10.1% | 13.3% | 17.4% | 11.8% |
| ROA | 2.6% | 2.6% | 3.2% | 3.2% | 2.1% | 5.4% | 3.5% | 2.2% | 2.5% | 3.5% | 2.5% |
| ROIC | 4.8% | 4.8% | 3.8% | 6.7% | 4.8% | 9.2% | 7.3% | 6.9% | 8.1% | 7.4% | 6.4% |
| ROCE | 7.0% | 7.0% | 4.8% | 8.6% | 6.4% | 11.6% | 9.0% | 8.1% | 8.5% | 8.0% | 7.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.82 | 1.82 | 1.35 | 2.87 | 3.71 | 3.49 | 2.72 | 2.37 | 3.20 | 2.59 | 2.75 |
| Debt / EBITDA | 7.80 | 7.80 | 5.73 | 5.93 | 8.47 | 5.20 | 5.82 | 6.58 | 5.32 | 5.23 | 6.15 |
| Net Debt / Equity | — | 1.81 | 1.32 | 2.84 | 3.64 | 3.43 | 2.37 | 2.19 | 3.03 | 2.47 | 2.65 |
| Net Debt / EBITDA | 7.74 | 7.74 | 5.60 | 5.86 | 8.31 | 5.12 | 5.07 | 6.09 | 5.04 | 5.00 | 5.93 |
| Debt / FCF | — | 9.61 | 4.90 | 12.67 | 53.56 | 21.24 | 4.45 | 14.48 | 9.54 | 527.28 | 14.27 |
| Interest Coverage | 3.32 | 3.32 | 2.36 | 2.92 | 2.54 | 5.63 | 3.12 | 2.32 | 2.12 | 2.31 | 1.78 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | 1.04 | 1.04 | 1.01 | 1.10 | 0.90 | 1.11 | 1.33 | 1.41 | 1.52 | 1.41 |
| Quick Ratio | 1.04 | 1.04 | 1.04 | 1.01 | 1.10 | 0.90 | 1.11 | 1.33 | 1.41 | 1.52 | 2.51 |
| Cash Ratio | 0.03 | 0.03 | 0.06 | 0.09 | 0.15 | 0.06 | 0.40 | 0.37 | 0.25 | 0.20 | 0.17 |
| Asset Turnover | — | 0.93 | 0.92 | 0.87 | 0.83 | 0.84 | 0.72 | 0.74 | 0.85 | 0.87 | 0.87 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 57.85 | 57.80 | 39.66 | 54.25 | 52.32 | 59.17 | 51.42 | 50.76 | 56.82 | 48.86 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.5% | 1.7% | 2.8% | 4.1% | 3.9% | 2.5% | — | — | — | — | — |
| Payout Ratio | 21.5% | 21.5% | 30.2% | 26.2% | 40.6% | 12.6% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.1% | 7.9% | 8.8% | 15.1% | 9.2% | 18.9% | 13.0% | 12.3% | 12.8% | 9.1% | 12.2% |
| FCF Yield | 18.7% | 20.9% | 23.0% | 22.6% | 5.7% | 10.7% | 45.6% | 17.6% | 30.3% | 0.4% | 20.2% |
| Buyback Yield | 4.9% | 5.5% | 1.6% | 0.8% | 11.7% | 3.9% | 0.8% | 2.4% | 0.6% | 0.4% | 0.3% |
| Total Shareholder Yield | 6.4% | 7.2% | 4.4% | 4.9% | 15.6% | 6.3% | 0.8% | 2.4% | 0.6% | 0.4% | 0.3% |
| Shares Outstanding | — | $124M | $125M | $123M | $125M | $130M | $130M | $130M | $130M | $129M | $128M |
Clinical labor wage inflation
According to current market data, Select Medical trades at a P/E of 14.02, which appears to reflect a conglomerate discount compared to pure-play peers, potentially obscuring the value of its integrated post-acute ecosystem and the proprietary data moat provided by its Concentra occupational health segment.
The forward P/E of 13.56 suggests that investors remain cautious regarding the company's ability to expand margins amidst persistent labor cost pressures. This valuation multiple warrants further investigation, as it may undervalue the strategic synergy of the joint venture model compared to the higher-multiple, de novo facility approach favored by competitors like The Ensign Group.
Based on reported figures, Select Medical's ROIC has remained consistently low, fluctuating between -3.0% and 2.3% over the last ten quarters, which suggests that the company is struggling to generate returns that meaningfully exceed its cost of capital in the current high-acuity care environment.
The inability to sustain a double-digit ROIC indicates that the capital-intensive nature of maintaining specialized medical facilities is currently outpacing the company's ability to drive operational efficiency. Investors should monitor whether future strategic shifts, such as a potential Concentra spin-off, could improve the aggregate return profile by shedding lower-margin assets.
As reported in recent financial statements, the company's asset turnover ratio has remained stagnant near 0.24, reflecting the significant capital investment required to maintain its broad footprint of critical illness recovery and rehabilitation hospitals relative to the revenue generated by these high-acuity assets.
The persistent volatility in DSO, which reached 79 days in 2024Q2, suggests that the company faces ongoing challenges in managing its cash conversion cycle, likely due to the complexity of government reimbursement and joint venture billing. This inefficiency appears to be a structural drag on the company's ability to optimize its working capital.
According to quarterly balance sheet data, Select Medical's debt-to-EBITDA ratio has exhibited extreme volatility, ranging from 8.35 to 45.26, which indicates that the company's ability to service its debt is highly susceptible to fluctuations in operating income and periodic refinancing requirements.
While the reported debt-to-equity ratio of 0.54 in 2026Q1 appears manageable, the underlying interest coverage ratio of 3.47 suggests that the company has limited room for error if clinical labor costs continue to compress operating margins. The reliance on joint venture partners to share financial risk appears to be a critical, yet volatile, component of the company's overall leverage strategy.
Based on an analysis of the company's structure, the consolidated net margin is frequently misapplied by analysts, as it fails to account for the significant non-controlling interests inherent in the joint venture model, thereby understating the true profitability attributable to Select Medical shareholders.
Investors should prioritize 'Net Income Attributable to Select Medical' over consolidated figures to avoid a distorted view of equity returns. Relying on headline net margins obscures the fact that a substantial portion of earnings is contractually shared with regional health system partners, making this metric a poor proxy for the company's actual operational performance.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SEM stock.
Select Medical Holdings Corporation's current P/E ratio is 14.0x. The historical average is 8.3x. This places it at the 100th percentile of its historical range.
Select Medical Holdings Corporation's current EV/EBITDA is 12.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.8x.
Select Medical Holdings Corporation's return on equity (ROE) is 7.3%. The historical average is 14.6%.
Based on historical data, Select Medical Holdings Corporation is trading at a P/E of 14.0x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Select Medical Holdings Corporation's current dividend yield is 1.54% with a payout ratio of 21.5%.
Select Medical Holdings Corporation has 11.5% gross margin and 6.1% operating margin.
Select Medical Holdings Corporation's Debt/EBITDA ratio is 7.8x, indicating high leverage. A ratio above 4x may signal elevated financial risk.